Prednicarbate Brand Name– Dermatop
What is Prednicarbate
Prednicarbate is a topical, low- to medium-potency, synthetic non-fluorinated and non-halogenated corticosteroid.
It is similar in potency to hydrocortisone. It is used to relieve the inflammatory and pruritic manifestations of mild to moderate corticosteroid-responsive dermatoses.
Prednicarbate has anti-inflammatory, antipruritic, and vasoconstrictive properties.
The cream may be used in pediatric patients 1 year of age and older, although the safety and efficacy of use for longer than 3 weeks has not been established.
Prednicarbate was initially approved by the FDA in 1991.
Indications
- alopecia
- atopic dermatitis
- contact dermatitis
- discoid lupus erythematosus
- eczema
- exfoliative dermatitis
- granuloma annulare
- keloids
- lichen planus
- lichen simplex
- lichen striatus
- necrobiosis lipoidica diabeticorum
- pemphigus
- pityriasis rosea
- polymorphous light eruption
- pompholyx
- prurigo
- pruritus
- psoriasis
- Rhus dermatitis
- sarcoidosis
- seborrheic dermatitis
- xerosis
Side Effects
- acneiform rash
- adrenocortical insufficiency
- cataracts
- contact dermatitis
- Cushing’s syndrome
- erythema
- folliculitis
- glycosuria
- growth inhibition
- headache
- hyperglycemia
- hypertension
- hypertrichosis
- hypothalamic-pituitary-adrenal (HPA) suppression
- impaired wound healing
- increased intracranial pressure
- infection
- maculopapular rash
- miliaria
- ocular hypertension
- papilledema
- pruritus
- pseudotumor cerebri
- purpura
- skin atrophy
- skin hypopigmentation
- skin irritation
- skin ulcer
- striae
- telangiectasia
- tolerance
- visual impairment
- withdrawal
- xerosis
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- acne rosacea
- acne vulgaris
- breast-feeding
- children
- corticosteroid hypersensitivity
- Cushing’s syndrome
- diabetes mellitus
- fungal infection
- geriatric
- growth inhibition
- herpes infection
- hypothalamic-pituitary-adrenal (HPA) suppression
- increased intracranial pressure
- infants
- infection
- measles
- neonates
- occlusive dressing
- ocular exposure
- ophthalmic administration
- perioral dermatitis
- pregnancy
- skin abrasion
- skin atrophy
- vaginal administration
- varicella
- viral infection
Interactions
- Metyrapone
Metyrapone: (Major) Medications which affect pituitary or adrenocortical function, including all corticosteroid therapy, should be discontinued prior to and during testing with metyrapone. Patients taking inadvertent doses of corticosteroids on the test day may exhibit abnormally high basal plasma cortisol levels and a decreased response to the test. Although systemic absorption of topical corticosteroids is minimal, temporary discontinuation of these products should be considered if possible to reduce the potential for interference with the test results.
